On the public citation graph

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis

https://doi.org/10.1007/s00228-015-1966-0

0 signed · 136 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.22513openalex-snapshot

The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer

inferredcites →https://doi.org/10.1007/s00432-010-0928-2openalex-snapshot

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

inferredcites →https://doi.org/10.1007/s12253-013-9715-0openalex-snapshot

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

inferredcites →https://doi.org/10.1016/j.canlet.2008.02.064openalex-snapshot

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

inferredcites →https://doi.org/10.1016/j.jse.2013.01.017openalex-snapshot

An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria

inferredcites →https://doi.org/10.1016/j.lungcan.2006.06.003openalex-snapshot

L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer

inferredcites →https://doi.org/10.1016/j.lungcan.2008.09.010openalex-snapshot

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

inferredcites →https://doi.org/10.1016/j.lungcan.2010.04.005openalex-snapshot

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

inferredcites →https://doi.org/10.1016/j.lungcan.2013.07.003openalex-snapshot

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

inferredcites →https://doi.org/10.1016/s0140-6736(06)68063-xopenalex-snapshot

Gefitinib for refractory advanced non-small-cell lung cancer

inferredcites →https://doi.org/10.1016/s0140-6736(06)68064-1openalex-snapshot

Gefitinib for refractory advanced non-small-cell lung cancer

inferredcites →https://doi.org/10.1016/s0895-4356(97)00049-8openalex-snapshot

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

inferredcites →https://doi.org/10.1016/s1470-2045(09)70364-xopenalex-snapshot

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(11)70184-xopenalex-snapshot

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

inferredcites →https://doi.org/10.1016/s1470-2045(11)70393-xopenalex-snapshot

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(13)70604-1openalex-snapshot

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(14)71173-8openalex-snapshot

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

inferredcites →https://doi.org/10.1016/s1556-0864(15)30013-7openalex-snapshot

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

inferredcites →https://doi.org/10.1038/sj.bjc.6603040openalex-snapshot

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

inferredcites →https://doi.org/10.1038/sj.bjc.6603393openalex-snapshot

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

inferredcites →https://doi.org/10.1038/sj.bjc.6603710openalex-snapshot

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

inferredcites →https://doi.org/10.1056/nejmoa044238openalex-snapshot

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

inferredcites →https://doi.org/10.1056/nejmoa0904554openalex-snapshot

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa0909530openalex-snapshot

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

inferredcites →https://doi.org/10.1056/nejmra0802714openalex-snapshot

Lung Cancer

inferredcites →https://doi.org/10.1093/annonc/mdv270openalex-snapshot

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

inferredcites →https://doi.org/10.1097/jto.0b013e31829f684aopenalex-snapshot

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1111/j.1524-4733.2008.00347.xopenalex-snapshot

Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons

inferredcites →https://doi.org/10.1136/bmj.331.7521.897openalex-snapshot

Simultaneous comparison of multiple treatments: combining direct and indirect evidence

inferredcites →https://doi.org/10.1136/bmj.b2700openalex-snapshot

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

inferredcites →https://doi.org/10.1136/jclinpath-2011-200169openalex-snapshot

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

inferredcites →https://doi.org/10.1148/radiol.13121824openalex-snapshot

Advanced Lung Adenocarcinoma Harboring a Mutation of the Epidermal Growth Factor Receptor: CT Findings after Tyrosine Kinase Inhibitor Therapy

inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1846openalex-snapshot

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-0462openalex-snapshot

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1660openalex-snapshot

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1159/000346844openalex-snapshot

Trastuzumab-Induced Hepatotoxicity: A Case Report

inferredcites →https://doi.org/10.1159/000347096openalex-snapshot

High Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer

inferredcites →https://doi.org/10.1186/1471-2288-10-54openalex-snapshot

Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial

inferredcites →https://doi.org/10.1200/jco.2005.01.388openalex-snapshot

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

inferredcites →https://doi.org/10.1200/jco.2005.05.4692openalex-snapshot

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

inferredcites →https://doi.org/10.1200/jco.2007.14.8494openalex-snapshot

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

inferredcites →https://doi.org/10.1200/jco.2007.15.6695openalex-snapshot

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

inferredcites →https://doi.org/10.1200/jco.2010.33.4235openalex-snapshot

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

inferredcites →https://doi.org/10.1200/jco.2012.44.2806openalex-snapshot

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

inferredcites →https://doi.org/10.1200/jco.2014.58.1736openalex-snapshot

Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer: A Meta-Analysis

inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.8072openalex-snapshot

The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major…

inferredcites →https://doi.org/10.1371/journal.pmed.0020073openalex-snapshot

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

inferredcites →https://doi.org/10.1371/journal.pmed.1000100openalex-snapshot

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

inferredcites →https://doi.org/10.1371/journal.pone.0107161openalex-snapshot

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

inferredcites →https://doi.org/10.1634/theoncologist.13-s1-5openalex-snapshot

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

inferredcites →https://doi.org/10.3322/caac.20073openalex-snapshot

Cancer Statistics, 2010

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3751803openalex-extracted

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

inferred← citeshttps://doi.org/10.1002/cam4.4268openalex-snapshot

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation

inferred← citeshttps://doi.org/10.1002/cam4.71319openalex-snapshot

Plasma‐Based Genomic Features Influencing Outcomes of T790M ‐Positive Non–Small Cell Lung Cancer Receiving Osimertinib

inferred← citeshttps://doi.org/10.1002/cncr.34553openalex-snapshot

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

inferred← citeshttps://doi.org/10.1007/s11060-023-04442-zopenalex-snapshot

EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease

inferred← citeshttps://doi.org/10.1007/s11523-023-00975-5openalex-snapshot

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

inferred← citeshttps://doi.org/10.1016/j.canlet.2018.03.005openalex-snapshot

Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment

inferred← citeshttps://doi.org/10.1016/j.ccell.2021.07.005openalex-snapshot

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

inferred← citeshttps://doi.org/10.1016/j.cllc.2016.05.018openalex-snapshot

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment

inferred← citeshttps://doi.org/10.1016/j.cllc.2020.05.019openalex-snapshot

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer

inferred← citeshttps://doi.org/10.1016/j.cllc.2021.10.009openalex-snapshot

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

inferred← citeshttps://doi.org/10.1016/j.crad.2018.10.001openalex-snapshot

Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma

inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100378openalex-snapshot

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

inferred← citeshttps://doi.org/10.1016/j.ejca.2021.09.041openalex-snapshot

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

inferred← citeshttps://doi.org/10.1016/j.esmoop.2023.101594openalex-snapshot

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases

inferred← citeshttps://doi.org/10.1016/j.ijrobp.2020.11.026openalex-snapshot

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

inferred← citeshttps://doi.org/10.1016/j.jtho.2016.11.2225openalex-snapshot

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients

inferred← citeshttps://doi.org/10.1016/j.jtocrr.2021.100171openalex-snapshot

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

inferred← citeshttps://doi.org/10.1016/j.jtocrr.2025.100912openalex-snapshot

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

inferred← citeshttps://doi.org/10.1016/j.lanepe.2023.100592openalex-snapshot

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108548openalex-snapshot

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108856openalex-snapshot

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

inferred← citeshttps://doi.org/10.1016/s1470-2045(19)30035-xopenalex-snapshot

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

inferred← citeshttps://doi.org/10.1016/s1470-2045(19)30634-5openalex-snapshot

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

inferred← citeshttps://doi.org/10.1038/s41598-017-00511-2openalex-snapshot

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma

inferred← citeshttps://doi.org/10.1038/s41598-022-18889-zopenalex-snapshot

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

inferred← citeshttps://doi.org/10.1038/s41598-025-03422-9openalex-snapshot

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

inferred← citeshttps://doi.org/10.1038/s41698-023-00490-wopenalex-snapshot

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

inferred← citeshttps://doi.org/10.1080/13696998.2024.2309838openalex-snapshot

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

inferred← citeshttps://doi.org/10.1093/noajnl/vdaa064openalex-snapshot

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases

inferred← citeshttps://doi.org/10.1097/md.0000000000012537openalex-snapshot

Score for lung adenocarcinoma in China with EGFR mutation of exon 19

inferred← citeshttps://doi.org/10.1097/md.0000000000035081openalex-snapshot

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer

inferred← citeshttps://doi.org/10.1097/ot9.0000000000000007openalex-snapshot

Analysis of EGFR Gene Mutations in Lung Adenocarcinoma in Karamay, Xinjiang

inferred← citeshttps://doi.org/10.1097/pcc.0000000000001388openalex-snapshot

Extracorporeal Cardiopulmonary Resuscitation in the Pediatric Cardiac Population: In Search of a Standard of Care*

inferred← citeshttps://doi.org/10.1101/2024.03.11.24304144openalex-snapshot

Radiotherapy combined with EGFR-TKIs for stage III EGFR-Mutated lung cancer: A retrospective cohort study

inferred← citeshttps://doi.org/10.1111/1759-7714.14079openalex-snapshot

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study

inferred← citeshttps://doi.org/10.1111/1759-7714.14267openalex-snapshot

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer

inferred← citeshttps://doi.org/10.1111/cas.14655openalex-snapshot

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

inferred← citeshttps://doi.org/10.1136/bmjresp-2022-001492openalex-snapshot

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer

inferred← citeshttps://doi.org/10.1148/rg.230136openalex-snapshot

2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation

inferred← citeshttps://doi.org/10.1155/2022/9399797openalex-snapshot

Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-21-0273openalex-snapshot

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1177/1758835919891652openalex-snapshot

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis

inferred← citeshttps://doi.org/10.1186/s12859-023-05430-wopenalex-snapshot

Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma

inferred← citeshttps://doi.org/10.1186/s12885-018-4691-0openalex-snapshot

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

inferred← citeshttps://doi.org/10.1186/s12885-023-11782-6openalex-snapshot

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

inferred← citeshttps://doi.org/10.1186/s12885-024-12573-3openalex-snapshot

eHSP90α in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma

inferred← citeshttps://doi.org/10.1186/s40981-025-00839-zopenalex-snapshot

Bridging via extracorporeal cardiopulmonary resuscitation for hemodynamic collapse in a patient with metastatic lung cancer: a case report

inferred← citeshttps://doi.org/10.1186/s41021-023-00289-yopenalex-snapshot

Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case–control study

inferred← citeshttps://doi.org/10.1200/jgo.2016.003392openalex-snapshot

Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer

inferred← citeshttps://doi.org/10.1200/po-25-00884openalex-snapshot

Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1245/s10434-018-6347-3openalex-snapshot

Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma

inferred← citeshttps://doi.org/10.1245/s10434-024-16806-4openalex-snapshot

Significance of Tumor Microvasculature in the Tumor Microenvironment in Adenocarcinoma with EGFR Common Mutations

inferred← citeshttps://doi.org/10.17116/onkolog20211006156openalex-snapshot

Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer

inferred← citeshttps://doi.org/10.21037/tcr.2020.01.24openalex-snapshot

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab

inferred← citeshttps://doi.org/10.21037/tlcr-22-683openalex-snapshot

Multiple mutations in the EGFR gene in lung cancer is rare but should not be forgettable

inferred← citeshttps://doi.org/10.21203/rs.3.rs-4467606/v1openalex-snapshot

Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study

inferred← citeshttps://doi.org/10.2147/cmar.s253760openalex-snapshot

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

inferred← citeshttps://doi.org/10.2174/1568009619666181210114559openalex-snapshot

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.2217/cer-2020-0189openalex-snapshot

Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings

inferred← citeshttps://doi.org/10.2217/fon-2021-0218openalex-snapshot

Real-World Characteristics and Outcomes of Advanced Non-Small-Cell Lung Cancer Patients with EGFR Exon 19 Deletions or Exon 21 Mutations

inferred← citeshttps://doi.org/10.26434/chemrxiv-2025-k329jopenalex-snapshot

Discovery of Novel EGFR Kinase Inhibitors Using a Wild-Type EGFR: A Computational Approach

inferred← citeshttps://doi.org/10.3389/fmed.2022.1001876openalex-snapshot

Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB

inferred← citeshttps://doi.org/10.3389/fmolb.2021.684661openalex-snapshot

ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study

inferred← citeshttps://doi.org/10.3389/fonc.2019.01485openalex-snapshot

The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma

inferred← citeshttps://doi.org/10.3389/fonc.2020.00904openalex-snapshot

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

inferred← citeshttps://doi.org/10.3389/fonc.2025.1514653openalex-snapshot

Clinical and molecular characteristics, therapeutic strategies, and prognosis of non-small cell lung cancer patients harboring primary and acquired BRAF mutations

inferred← citeshttps://doi.org/10.3389/fphar.2025.1503171openalex-snapshot

Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients

inferred← citeshttps://doi.org/10.3389/fpubh.2026.1858476openalex-snapshot

Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China

inferred← citeshttps://doi.org/10.3390/cancers14020309openalex-snapshot

Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy

inferred← citeshttps://doi.org/10.3390/cancers14102519openalex-snapshot

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis

inferred← citeshttps://doi.org/10.3390/cancers14246127openalex-snapshot

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.3390/curroncol32080414openalex-snapshot

Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto

inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2019.02.04openalex-snapshot

[Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy in Advanced NSCLC Patients with EGFR Mutations].

inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2019.09.02openalex-snapshot

[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population].

inferred← citeshttps://doi.org/10.3892/etm.2021.10584openalex-snapshot

How specific molecular‑targeted agents can make obsolete a ‘one size fits all’ approach in EGFR‑mutated NSCLC treatment (Review)

inferred← citeshttps://doi.org/10.3892/mco.2025.2874openalex-snapshot

Association of the expression of 5‑FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S‑1 adjuvant chemotherapy: Follow‑up results of the Setouchi Lung Cancer Group Study 1201

inferred← citeshttps://doi.org/10.3904/kjim.2016.190openalex-snapshot

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

inferred← citeshttps://doi.org/10.4143/crt.2020.459openalex-snapshot

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

inferred← citeshttps://doi.org/10.4143/crt.2023.453openalex-snapshot

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

inferred← citeshttps://doi.org/10.4143/crt.2024.1177openalex-snapshot

The Profile of Gut Microbiota in Carcinogenesis Driven by Mutant EGFR in Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.47836/mjmhs.19.2.48openalex-snapshot

Intermittent EGFR-TKI Therapy is Associated with Durable Response in Advanced EGFR-Mutant NSCLC: A Case Report

inferred← citeshttps://doi.org/10.53771/ijbpsa.2024.7.1.0018openalex-snapshot

In vitro regeneration of exotic fruit dragon (Hylocereus undatus) from stem fraction

inferred← citeshttps://doi.org/10.6084/m9.figshare.26289094openalex-snapshot

Additional file 1 of eHSP90α in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma

inferred← citeshttps://doi.org/10.7759/cureus.25446openalex-snapshot

Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.